JP Morgan Chase
FATE icon

JP Morgan Chase’s Fate Therapeutics FATE Stock Holding History

JP Morgan Chase’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-132,000
Closed -$2.93M – 5468
2020
Q1 		$2.93M Buy
132,000
+57,000
+76% +$1.44M ﹤0.01% 2684
2019
Q4 		$1.47M Buy
+75,000
New +$1.19M ﹤0.01% 3607

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's FATE Position: Q1 2026 in Review

JP Morgan Chase increased its Fate Therapeutics (FATE) stake by 3.3% in Q1 2026, buying an estimated $1.77K and bringing the position to 44,888 shares worth $50.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6190.

JP Morgan Chase first reported a position in FATE in Q3 2016 and has held it in 38 quarters since. The position peaked at $136M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • JP Morgan Chase held 44,888 shares of Fate Therapeutics worth $50.7K as of Q1 2026.
  • JP Morgan Chase bought 1,452 Fate Therapeutics shares in Q1 2026, an estimated $1.77K.
  • Fate Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6190 holding.
  • JP Morgan Chase first reported a position in Fate Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • JP Morgan Chase's Fate Therapeutics position peaked at $136M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.